Genetic variation of CTNNB1 gene is associated with susceptibility and prognosis of gastric cancer in a Chinese population

Mutagenesis

Volumn 27, Issue 6, 2012, Pages 623-630

  Wang, Shizhi ^a   Tian, Yuanyuan ^a,b   Wu, Dongmei ^a   Zhu, Haixia ^a,c   Luo, Dewei ^a   Gong, Weida ^d   Zhou, Yan ^e   Zhou, Jianwei ^a   Zhang, Zhengdong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b WUXI NO 2 PEOPLE S HOSPITAL   (China)

^c Nantong Cancer Hospital   (China)

^d Yixing Tumor Hospital   (China)

^e YIXING PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARDIA; CLINICAL FEATURE; CONTROLLED STUDY; CTNNB1 GENE; DISTANT METASTASIS; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TUMOR GENE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BETA CATENIN; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SOFTWARE; STOMACH NEOPLASMS;

EID: 84868532244     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/ges027     Document Type: Article

References (38)

1. Hartgrink, H. H., Jansen, E. P., van Grieken, N. C. and van de Velde, C. J. (2009) Gastric cancer. Lancet, 374, 477-490.
2. Parkin, D. M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
3. Catalano, V., Labianca, R., Beretta, G. D., Gatta, G., de Braud, F. and Van Cutsem, E. (2009) Gastric cancer. Crit. Rev. Oncol. Hematol., 71, 127-164.
4. Ludwig, J. A. and Weinstein, J. N. (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer, 5, 845-856.
5. Lao-Sirieix, P., Caldas, C. and Fitzgerald, R. C. (2010) Genetic predisposition to gastro-oesophageal cancer. Curr. Opin. Genet. Dev., 20, 210-217.
6. Dong, L. M., Potter, J. D., White, E., Ulrich, C. M., Cardon, L. R. and Peters, U. (2008) Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA, 299, 2423-2436.
7. van Amerongen, R. and Nusse, R. (2009) Towards an integrated view of Wnt signaling in development. Development, 136, 3205-3214.
8. Arozarena, I., Bischof, H., Gilby, D., Belloni, B., Dummer, R. and Wellbrock, C. (2011) In melanoma, beta-catenin is a suppressor of invasion. Oncogene, 30, 4531-4543.
9. Wang, Y., Krivtsov, A. V., Sinha, A. U., North, T. E., Goessling, W., Feng, Z., Zon, L. I. and Armstrong, S.A. (2010) The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science, 327, 1650-1653.
10. Barker, N. and Clevers, H. (2006) Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov., 5, 997-1014.
11. MacDonald, B. T., Tamai, K. and He, X. (2009) Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell, 17, 9-26.
12. Clements, W. M., Wang, J., Sarnaik, A., Kim, O. J., MacDonald, J., Fenoglio-Preiser, C., Groden, J. and Lowy, A. M. (2002) Beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. Cancer Res., 62, 3503-3506.
13. Ragazzon, B., Libe, R., Gaujoux, S., et al. (2010) Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res., 70, 8276-8281.
14. Nunez, F., Bravo, S., Cruzat, F., Montecino, M. and De Ferrari, G. V. (2011) Wnt/beta-catenin signaling enhances cyclooxygenase-2 (COX2) transcrip-tional activity in gastric cancer cells. PLoS One, 6, e18562.
15. Mishra, L., Shetty, K., Tang, Y., Stuart, A. and Byers, S. W. (2005) The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene, 24, 5775-5789.
16. Wu, W. K., Cho, C. H., Lee, C. W., Fan, D., Wu, K., Yu, J. and Sung, J. J. (2010) Dysregulation of cellular signaling in gastric cancer. Cancer Lett., 295, 144-153.
17. Bjorklund, P., Lindberg, D., Akerstrom, G. and Westin, G. (2008) Stabilizing mutation of CTNNB1/beta-catenin and protein accumulation analyzed in a large series of parathyroid tumors of Swedish patients. Mol. Cancer, 7, 53.
18. Chesire, D. R., Ewing, C. M., Sauvageot, J., Bova, G. S. and Isaacs, W. B. (2000) Detection and analysis of beta-catenin mutations in prostate cancer. Prostate, 45, 323-334.
19. Ebert, M. P., Fei, G., Kahmann, S., Muller, O., Yu, J., Sung, J. J. and Malfertheiner, P. (2002) Increased beta-catenin mRNA levels and mutational alterations of the APC and beta-catenin gene are present in intestinal-type gastric cancer. Carcinogenesis, 23, 87-91.
20. Park, W. S., Oh, R. R., Park, J. Y. et al. (1999) Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res., 59, 4257-4260.
21. Candidus, S., Bischoff, P., Becker, K. F. and Hofer, H. (1996) No evidence for mutations in the alpha-and beta-catenin genes in human gastric and breast carcinomas. Cancer Res., 56, 49-52.
22. Nojima, M., Suzuki, H., Toyota, M., et al. (2007) Frequent epigenetic inac-tivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene, 26, 4699-4713.
23. Tong, J. H., To, K. F., Ng, E. K., et al. (2001) Somatic beta-catenin mutation in gastric carcinoma-an infrequent event that is not specifc for microsatellite instability. Cancer Lett., 163, 125-130.
24. Andrew, A. S., Gui, J., Sanderson, A. C. et al. (2009) Bladder cancer SNP panel predicts susceptibility and survival. Hum. Genet., 125, 527-539.
25. Huang, S. P., Ting, W. C., Chen, L. M. et al. (2010) Association analysis of Wnt pathway genes on prostate-specifc antigen recurrence after radical prostatectomy. Ann. Surg. Oncol., 17, 312-322.
26. Wang, M., Bai, J., Tan, Y. et al. (2011) Genetic variant in PSCA predicts survival of diffuse-type gastric cancer in a Chinese population. Int. J. Cancer, 129, 1207-1213.
27. Lauren, P. (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classifcation. Acta Pathol. Microbiol. Scand., 64, 31-49.
28. Green, F. L., Page, D. L., Fleming, I. D., Fritz, A. G., Balch, C. M., Haller, D. G. and Morrow, M.H., eds. (2002) Stomach of the digestive system. In AJCC Cancer Staging Handbook. Springer Press, New York, pp. 111-118.
29. Barrett, J. C., Fry, B., Maller, J. and Daly, M. J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
30. Park, S. R., Kong, S. Y., Nam, B. H. et al. (2011) CYP2A6 and ERCC1 polymorphisms correlate with effcacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br. J. Cancer, 104, 1126-1134.
31. Yin, M., Yan, J., Martinez-Balibrea, E. et al. (2011) ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin. Cancer Res., 17, 1632-1640.
32. Starinsky, S., Figer, A., Ben-Asher, E., Geva, R., Flex, D., Fidder, H. H., Zidan, J., Lancet, D. and Friedman, E. (2005) Genotype phenotype correlations in Israeli colorectal cancer patients. Int. J. Cancer, 114, 58-73.
33. Lee, J. Y., Park, A. K., Lee, K. M. et al. (2009) Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women. Carcinogenesis, 30, 1528-1531.
34. Modrek, B., Resch, A., Grasso, C. and Lee, C. (2001) Genome-wide detection of alternative splicing in expressed sequences of human genes. Nucleic Acids Res., 29, 2850-2859.
35. Wang, M., Yuan, L., Wu, D., Zhang, Z., Yin, C., Fu, G. and Wei, Q. (2010) A novel XPF-357A>C polymorphism predicts risk and recurrence of bladder cancer. Oncogene, 29, 1920-1928.
36. Camargo, M. C., Anderson, W. F., King, J. B., Correa, P., Thomas, C. C., Rosenberg, P. S., Eheman, C. R. and Rabkin, C. S. (2011) Divergent trends for gastric cancer incidence by anatomical subsite in US adults. Gut, 60, 1644-1649.
37. von Rahden, B. H., Stein, H. J. and Siewert, J. R. (2006) Surgical management of esophagogastric junction tumors. World J. Gastroenterol., 12, 6608-6613.
38. Gschwend, J. E., Dahm, P. and Fair, W. R. (2002) Disease specifc survival as endpoint of outcome for bladder cancer patients following radical cys-tectomy. Eur. Urol., 41, 440-448.